Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Oligonucleotide-based Therapy Medicinal Product Market by Type
 5.1 Oligonucleotide-based Therapy Medicinal Product Market Overview Snapshot and Growth Engine
 5.2 Oligonucleotide-based Therapy Medicinal Product Market Overview
 5.3 Antisense Oligonucleotides (ASO)
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Antisense Oligonucleotides (ASO): Geographic Segmentation
 5.4 siRNA
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 siRNA: Geographic Segmentation
 5.5 mRNA
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 mRNA: Geographic Segmentation

Chapter 6: Oligonucleotide-based Therapy Medicinal Product Market by Application
 6.1 Oligonucleotide-based Therapy Medicinal Product Market Overview Snapshot and Growth Engine
 6.2 Oligonucleotide-based Therapy Medicinal Product Market Overview
 6.3 Neuromuscular Diseases
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Neuromuscular Diseases: Geographic Segmentation
 6.4 hATTR
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 hATTR: Geographic Segmentation
 6.5 COVID-19
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 COVID-19: Geographic Segmentation
 6.6 Other
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Other: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Oligonucleotide-based Therapy Medicinal Product Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Oligonucleotide-based Therapy Medicinal Product Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Oligonucleotide-based Therapy Medicinal Product Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 SAREPTA THERAPEUTICS
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 IONIS PHARMACEUTICALS
 7.4 ALNYLAM
 7.5 BIOGEN
 7.6 NIPPON SHINYAKU
 7.7 SOBI
 7.8 NOVARTIS
 7.9 BIONTECH
 7.10 PFIZER
 7.11 MODERNA THERAPEUTICS
 7.12 JAZZ PHARMACEUTICALS
 7.13 CUREVAC
 7.14 REGULUS THERAPEUTICS
 7.15 PROQR
 7.16 SECARNA
 7.17 MINA THERAPEUTICS
 7.18 SYLENTIS
 7.19 ARROWHEAD
 7.20 SILENCE THERAPEUTICS
 7.21 DICERNA

Chapter 8: Global Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 Antisense Oligonucleotides (ASO)
  8.2.2 siRNA
  8.2.3 mRNA
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Neuromuscular Diseases
  8.3.2 hATTR
  8.3.3 COVID-19
  8.3.4 Other

Chapter 9: North America Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Antisense Oligonucleotides (ASO)
  9.4.2 siRNA
  9.4.3 mRNA
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Neuromuscular Diseases
  9.5.2 hATTR
  9.5.3 COVID-19
  9.5.4 Other
 9.6 Historic and Forecast Market Size by Country
  9.6.1 US
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Eastern Europe Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Antisense Oligonucleotides (ASO)
  10.4.2 siRNA
  10.4.3 mRNA
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Neuromuscular Diseases
  10.5.2 hATTR
  10.5.3 COVID-19
  10.5.4 Other
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Bulgaria
  10.6.2 The Czech Republic
  10.6.3 Hungary
  10.6.4 Poland
  10.6.5 Romania
  10.6.6 Rest of Eastern Europe

Chapter 11: Western Europe Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Antisense Oligonucleotides (ASO)
  11.4.2 siRNA
  11.4.3 mRNA
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Neuromuscular Diseases
  11.5.2 hATTR
  11.5.3 COVID-19
  11.5.4 Other
 11.6 Historic and Forecast Market Size by Country
  11.6.1 Germany
  11.6.2 UK
  11.6.3 France
  11.6.4 Netherlands
  11.6.5 Italy
  11.6.6 Russia
  11.6.7 Spain
  11.6.8 Rest of Western Europe

Chapter 12: Asia Pacific Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Antisense Oligonucleotides (ASO)
  12.4.2 siRNA
  12.4.3 mRNA
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Neuromuscular Diseases
  12.5.2 hATTR
  12.5.3 COVID-19
  12.5.4 Other
 12.6 Historic and Forecast Market Size by Country
  12.6.1 China
  12.6.2 India
  12.6.3 Japan
  12.6.4 South Korea
  12.6.5 Malaysia
  12.6.6 Thailand
  12.6.7 Vietnam
  12.6.8 The Philippines
  12.6.9 Australia
  12.6.10 New Zealand
  12.6.11 Rest of APAC

Chapter 13: Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Antisense Oligonucleotides (ASO)
  13.4.2 siRNA
  13.4.3 mRNA
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Neuromuscular Diseases
  13.5.2 hATTR
  13.5.3 COVID-19
  13.5.4 Other
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Turkey
  13.6.2 Bahrain
  13.6.3 Kuwait
  13.6.4 Saudi Arabia
  13.6.5 Qatar
  13.6.6 UAE
  13.6.7 Israel
  13.6.8 South Africa

Chapter 14: South America Oligonucleotide-based Therapy Medicinal Product Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 Antisense Oligonucleotides (ASO)
  14.4.2 siRNA
  14.4.3 mRNA
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Neuromuscular Diseases
  14.5.2 hATTR
  14.5.3 COVID-19
  14.5.4 Other
 14.6 Historic and Forecast Market Size by Country
  14.6.1 Brazil
  14.6.2 Argentina
  14.6.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Oligonucleotide-based Therapy Medicinal Product Scope:

Report Data	Oligonucleotide-based Therapy Medicinal Product Market
Oligonucleotide-based Therapy Medicinal Product Market Size in 2022	USD 368.4 million
Oligonucleotide-based Therapy Medicinal Product CAGR 2023 - 2030	4.5%
Oligonucleotide-based Therapy Medicinal Product Base Year	2022
Oligonucleotide-based Therapy Medicinal Product Forecast Data	2023 - 2030
Segments Covered	By Type, By Application, And by Regions
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna.
Key Segments	By Type Antisense Oligonucleotides (ASO) siRNA mRNA By Applications Neuromuscular Diseases hATTR COVID-19 Other